Cannabidiol (CBD), when derived from marijuana, is a Schedule 1 controlled substance under the federal law and is believed to be a “safe drug with no addictive effects” by Nora Volkow, director of the US National Institute on Drug Abuse (NIDA). In an op-ed published by The Huffington Post, she 
stated it to be a non psychotropic cannabinoid and that it may be therapeutic based on some preliminary data.
In both preclinical studies and clinical observational trials, CBD has been documented to have therapeutic mechanisms such as anti-cancer properties and anti-seizure activity in humans. If patients are generally well, usage of CBD is “safe and well tolerated” as per safety trials data.
The Obama administration has been urged by some senators to know the exact scientific and medical advancement of CBD, as well as at look at programs that could be expanded upon for pediatric epilepsy treatment.